dc.contributor.author | Assemblée mondiale de la Santé, 16 | |
dc.date.accessioned | 2015-09-16T14:04:23Z | |
dc.date.available | 2015-09-16T14:04:23Z | |
dc.date.issued | 1963 | |
dc.identifier.govdoc | A16/21 | |
dc.identifier.uri | https://iris.who.int/handle/10665/184619 | |
dc.language.iso | fr | en_US |
dc.publisher | Organisation mondiale de la Santé | en_US |
dc.subject | International Health Regulations | en_US |
dc.subject | Pharmaceutical products | en_US |
dc.subject.mesh | Communicable Disease Control | en_US |
dc.subject.mesh | Disease Outbreaks | en_US |
dc.subject.mesh | Sanitation | en_US |
dc.subject.mesh | Disease Notification | en_US |
dc.subject.mesh | Quarantine | en_US |
dc.subject.mesh | Pharmaceutical Preparations | en_US |
dc.subject.mesh | Drug Evaluation | en_US |
dc.subject.mesh | Substance-Related Disorders | en_US |
dc.title | Cinquième rapport de la Commission du Programme et du Budget | en_US |
dc.type | Governing body documents | en_US |
dc.subject.meshqualifier | prevention and control | en_US |